Skip to main content
. 2021 Jan 7;35(2):485–493. doi: 10.1038/s41375-020-01107-y

Fig. 3. Survival by Ruxolitinib exposure and discontinuation.

Fig. 3

Kaplan Meier survival estimates stratified by the use and discontinuation of Ruxo in the full analysis set (A) and after PS matching (B). P-values are calculated by log-rank test. PS propensity score, Ruxo ruxolitinib.